Chinese domestic crown disease oral medicine is put into production.
According to the surging news report, Coronary Pharmaceutical Group Co., Ltd.'s crown disease oral administration medicine was held in Jiangsu and Hainan on Saturday (February 11).Xianmang Pharmaceutical announced that starting today, Nuo Xin will supply various medical institutions one after another.
According to the health client of the People's Daily, Yu Qingqing, executive deputy general manager of Hainan Xianyou Pharmaceutical, said that after the production of the first year, the annual production capacity will reach tens of millions.The layout has been gradually completed, and production will gradually enter the right track from February.
Xian Nuoxin was specially approved by the National Drug Administration of China on January 28, and was listed in China.Xian Nuoxin is an adult patient who is used for oral small molecular crown disease infection to treat mild moderate new coronary virus infections (COVID-19).
In terms of price, Xian Nuoxin's first offer is 750 yuan (RMB, about S $ 147)/box.On February 8th, the National Medical Insurance Bureau of China issued a notice saying that domestic coronary drugs such as Xian Nuo Xin belonged to the scope of new coronary virus infection diagnosis and treatment plan (trial tenth edition) to enter the national temporary medical insurance and included the payment scope of the basic medical insurance fund in this province.Pay until March 31 this year.
